Infrastructure
for personalised
gene therapy
in Europe.

Gene and cell therapies have matured from speculative biology into an approved category of medicine. Twenty-plus ATMPs are now authorised in Europe; dozens more sit in pivotal trials; the science, contested only a decade ago, is settled. The barrier is no longer whether these therapies work. The barrier is the system through which they reach the patients for whom they were designed. Today, that system is expensive, geographically locked to a small number of academic centres, and slow in ways that compound — each handoff between a diagnostic lab, a manufacturing site, a clinical centre, and a payer adds weeks, errors, and cost. For a disease that progresses on the timescale of months, this is not a logistics problem. It is a definition of who gets treated.

The next decade rewires this. Manufacturing footprints shrink as closed automated platforms displace open-process cleanrooms; allogeneic and gene-corrected products replace one-shot autologous batches for many indications; in-vivo delivery removes the cell-handling step entirely for a growing class. Regulators are converging — IVDR, the ATMP regulation, and Germany's § 4b AMG hospital-exemption framework now provide a workable path for individualised therapies that did not exist in 2018. What does not yet exist is the connective tissue. The molecule is approved; the manufacturing platform is built; the clinic is willing — and yet bringing a single patient through the full pathway still requires a custom integration each time, hand-stitched across institutions that do not share registries, identifiers, transport protocols, or evidence formats.

What is missing is infrastructure in the sense that infrastructure is meant: a substrate that is operated by someone, available to everyone working on top of it, and built to standards that outlive any one operator on it. The shape of that infrastructure is now legible. It is a layer that takes responsibility for the patient-facing handoffs no single developer wants to operate alone — genetic identification, eligibility under genetic-testing law, compliant sourcing and transport, longitudinal evidence — and presents them to ATMP developers, clinical institutions, and regulators in a form they can each rely on. It is a layer that the developer of a muscle stem-cell therapy in Bonn, the academic medical centre in Berlin, the cell-processing facility in Frankfurt, and the federal regulator in Langen can each treat as a fact of the environment.

Atlas operates that layer. We do not develop drugs. We operate the pathway. The genetic identification that finds the eligible patient runs on Atlas Protocol, our diagnostic and intelligence surface. The compliant sourcing and inter-institutional transport runs on Atlas Logistics. The longitudinal monitoring that turns a single dose into a longitudinal evidence record — methylation panels, expression tracking, outcome registry — runs on Atlas Therapy. Manufacturing and re-implantation remain with the therapeutic developers and clinical centres who do them better than anyone. Atlas's responsibility is the orchestration: the part of the system that, if no one operates it deliberately, no one does. The thesis of this page is the thesis of the company. The molecule has been the bottleneck for forty years. For the next forty, the bottleneck will be the infrastructure on which the molecule travels. Atlas is operating it.